{
    "4565124": {
        "id": 4565124,
        "significance": "1",
        "headline": "Abbvie Says Q2 Reported And Adj EPS Expected To Include Acquired IPR&D And Milestones Expense Of $269 Mln On Pre-Tax Basis",
        "description": "July 6 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE - REPORTED GAAP EARNINGS & ADJUSTED. NON-GAAP EARNINGS FOR Q2 EXPECTED TO INCLUDE ACQUIRED IPR&D AND MILESTONES EXPENSE OF $269 MILLION ON PRE-TAX BASIS.FULL-YEAR 2022 ADJUSTED EARNINGS PER SHARE GUIDANCE RANGE, INCLUDING IMPACT OF Q2 2022 ACQUIRED IPR&D AND MILESTONES EXPENSE, IS $13.78 - $13.98.Q2 2022 ADJUSTED EARNINGS PER SHARE GUIDANCE RANGE, INCLUDING IMPACT OF Q2 2022 ACQUIRED IPR&D AND MILESTONES EXPENSE, IS $3.24 - $3.28.ABBVIE - 2022 ADJUSTED. DILUTED EPS GUIDANCE PREVIOUSLY ANNOUNCED, EXCLUDED IMPACT OF ACQUIRED IPR&D & MILESTONES EXPENSE THAT MAY BE INCURRED BEYOND Q1.Q2 EARNINGS PER SHARE VIEW $3.43 -- REFINITIV IBES DATA.FY2022 EARNINGS PER SHARE VIEW $14.01 -- REFINITIV IBES DATA.",
        "parentTopics": "Corporate Guidance"
    },
    "4574481": {
        "id": 4574481,
        "significance": "1",
        "headline": "Abbvie Says Qtrly Earnings Per Share $0.51; Qtrly Adjusted Earnings Per Share $3.37",
        "description": "July 29 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE - QTRLY GAAP EARNINGS PER SHARE $0.51 ; QTRLY ADJUSTED. EARNINGS PER SHARE $3.37.ABBVIE - CONFIRMS 2022 ADJUSTED. DILUTED EPS GUIDANCE RANGE OF $13.78-$13.98.ABBVIE - QTRLY NET REVENUES $14.58 BILLION, UP 4.5% ON A REPORTED BASIS AND UP 6.1% OPERATIONALLY.ABBVIE - 2022 ADJUSTED. PROFIT GUIDANCE INCLUDES UNFAVORABLE IMPACT OF $0.23\\/SHARE RELATED ACQUIRE IPR&D AND MILESTONES EXPENSE INCURRED YTD.ABBVIE - SKYRIZI & RINVOQ ARE ON PACE TO DELIVER ABOUT $7.5 BILLION IN COMBINED ANNUAL SALES.ABBVIE - QTRLY RESULTS INCLUDE UNFAVORABLE IMPACT OF $0.14\\/SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE.ABBVIE - QTRLY GLOBAL\tHUMIRA\tNET REVENUES OF $5.363 BILLION, UP 5.8% ON REPORTED BASIS, OR UP 6.8% ON OPERATIONAL BASIS.ABBVIE - QTRLY GLOBAL\tSKYRIZI\tNET REVENUES $1.252 BILLION, UP 85.9% ON A REPORTED BASIS, OR UP 88.3% OPERATIONALLY.ABBVIE - QTRLY GLOBAL RINVOQ NET REVENUES $592 MILLION, UP 56.3% ON REPORTED BASIS, UP 60.7% OPERATIONALLY.ABBVIE - QTRLY GLOBAL\tNET REVENUES\tFROM AESTHETICS PORTFOLIO $1.371 BILLION, DOWN 4.4%\tON REPORTED BASIS, OR DOWN 2.1% OPERATIONALLY.ABBVIE - IN QUARTER, ITEMS RELATED TO LITIGATION MATTERS IMPACTED RESULTS BY $2,203 MILLION PRE-TAX.ABBVIE - IN QUARTER, ITEMS RELATED TO LITIGATION MATTERS INCLUDE CHARGES FOR POTENTIAL LITIGATION SETTLEMENT INVOLVING ALLERGAN'S PAST SALES OF OPIOID PRODUCTS.Q2 EARNINGS PER SHARE VIEW $3.31, REVENUE VIEW $14.64 BILLION -- REFINITIV IBES DATA.",
        "parentTopics": "Corporate Guidance"
    },
    "4603984": {
        "id": 4603984,
        "significance": "1",
        "headline": "Abbvie Says Q3 Earnings Expected To Include Certain Expense Of $40 Million",
        "description": "Oct 5 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE - GAAP AND NON-GAAP EARNINGS FOR Q3 ARE EXPECTED TO INCLUDE ACQUIRED IPR&D AND MILESTONES EXPENSE OF $40 MILLION ON A PRE-TAX BASIS.ABBVIE -  IPR&D AND MILESTONES EXPENSE REPRESENTS AN UNFAVORABLE IMPACT OF $0.02 TO BOTH GAAP DILUTED EPS AND ADJUSTED NON-GAAP DILUTED EPS.ABBVIE -  FULL-YEAR 2022 ADJUSTED DILUTED EPS GUIDANCE RANGE, INCLUDING THE IMPACT OF Q3 ACQUIRED IPR&D AND MILESTONES EXPENSE, IS $13.76 - $13.96.ABBVIE - Q3 ADJUSTED DILUTED EPS GUIDANCE RANGE, INCLUDING THE IMPACT OF THIRD QUARTER 2022 ACQUIRED IPR&D AND MILESTONES EXPENSE, IS $3.53 - $3.57.Q3 EARNINGS PER SHARE VIEW $3.60 -- REFINITIV IBES DATA.FY2022 EARNINGS PER SHARE VIEW $13.87 -- REFINITIV IBES DATA.Further company coverage: <ABBV.N>. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4614137": {
        "id": 4614137,
        "significance": "1",
        "headline": "Abbvie Reports Quarterly GAAP Earnings Per Share $2.21 QTRLY Adjusted. Earnings Per Share $3.66",
        "description": "Oct 28 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE - QTRLY GAAP EARNINGS PER SHARE $2.21 ; QTRLY ADJUSTED. EARNINGS PER SHARE $3.66.ABBVIE - QTRLY NET REVENUES $14.812 BILLION, AN INCREASE OF 3.3% ON A REPORTED BASIS AND 5.4% OPERATIONALLY.ABBVIE - QTRLY GLOBAL HUMIRA NET REVENUES OF $5.559 BILLION INCREASED 2.5 % ON A REPORTED\tBASIS, OR 3.9 % ON A OPERATIONAL BASIS.ABBVIE - QTRLY GLOBAL NET\tREVENUES FROM AESTHETICS\tPORTFOLIO WERE $1.301 BILLION,\tAN INCREASE OF 4.0 % ON A REPORTED\tBASIS, OR 8.1 % ON AN OPERATIONAL BASIS.ABBVIE - QTRLY GLOBAL RINVOQ NET REVENUES\tWERE $695 MILLION, AN INCREASE OF 53.5 % ON A REPORTED BASIS OR 59.3 % ON AN OPERATIONAL BASIS.ABBVIE - QTRLY GLOBAL SKYRIZI NET REVENUES WERE $1.397 BILLION, AN INCREASE OF 75.4 % ON A REPORTED BASIS OR 78.3% ON AN OPERATIONAL BASIS.ABBVIE - CONFIRMS MIDPOINT OF 2022\tADJUSTED DILUTED EPS GUIDANCE RANGE, NARROWS RANGE FROM $13.76 - $13.96 TO\t$13.84 - $13.88.ABBVIE -QTRLY RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $0.02\t PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES\tEXPENSE.ABBVIE - 2022 ADJUSTED EPS GUIDANCE RANGE INCLUDES UNFAVORABLE IMPACT OF $0.25\\/SHARE RELATED TO ACQUIRED IPR&D, MILESTONES EXPENSE INCURRED YTD THROUGH Q3.ABBVIE - ANNOUNCES 2023 DIVIDEND INCREASE OF 5.0% ,\tBEGINNING WITH DIVIDEND PAYABLE IN FEB 2023.ABBVIE INC <<<ABBV.N>>> Q3 SHR VIEW $3.57, REV VIEW $14.91 BLN -- REFINITIV IBES DATA.",
        "parentTopics": "Corporate Guidance"
    },
    "4614266": {
        "id": 4614266,
        "significance": "1",
        "headline": "Abbvie Expects 2022 Sales Of $5.3 Bln For Medical Aesthetic Products",
        "description": "Oct 28 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE CEO SAYS PRESSURE ON CONSUMER SPENDING CORRELATES WITH SLOWDOWN IN PROCEDURES FOR AESTHETIC PRODUCTS.ABBVIE CEO EXPECTS MODERATING MARKET GROWTH IN NEAR TO MEDIUM TERM FOR JUVEDERM FROM LOWER DISCRETIONARY SPENDING.ABBVIE CEO EXPECTS STRONG ACCESS FOR U.S. HUMIRA THROUGHOUT 2023, AND SEES BIOSIMILARS SHARING ACCESS AS THEY BECOME AVAILABLE.ABBVIE EXPECTS 2022 SALES OF $5.3 BILLION FOR MEDICAL AESTHETIC PRODUCTS.ABBVIE EXPECTS 2022 SALES OF ABOUT $2 BILLION FOR CANCER DRUG VENCLEXTA.ABBVIE CEO GONZALEZ SAYS HIS TRANSITION FROM ROLE WOULD NOT TAKE PLACE UNTIL HUMIRA BIOSIMILARS ENTER THE U.S. MARKET AND CO IS CONFIDENT ABOUT BUSINESS.Further company coverage: ABBV.N. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Restructuring\\/Reorganization\\/Related"
    },
    "4643145": {
        "id": 4643145,
        "significance": "1",
        "headline": "Abbvie - Reported GAAP Earnings And Adjusted Earnings For Q4 Are Expected To Include Acquired Ipr&D And Milestones Expense Of $243 Million On A Pre-Tax Basis",
        "description": "Jan 6 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE - REPORTED GAAP EARNINGS AND ADJUSTED EARNINGS FOR Q4 ARE EXPECTED TO INCLUDE ACQUIRED IPR&D AND MILESTONES EXPENSE OF $243 MILLION ON A PRE-TAX BASIS.2022 ADJUSTED DILUTED EPS GUIDANCE RANGE, INCLUDING IMPACT OF FOURTH QUARTER 2022 ACQUIRED IPR&D AND MILESTONES EXPENSE, IS $13.70 - $13.74.Q4 2022 ADJUSTED EARNINGS PER SHARE GUIDANCE RANGE, INCLUDING IMPACT OF Q4 2022 ACQUIRED IPR&D AND MILESTONES EXPENSE, IS $3.51 - $3.55.DOES NOT FORECAST ACQUIRED IPR&D AND MILESTONES EXPENSE DUE TO UNCERTAINTY OF FUTURE OCCURRENCE AND TIMING OF THESE TRANSACTIONS.Q4 EARNINGS PER SHARE VIEW $3.67 -- REFINITIV IBES DATA.Further company coverage: <ABBV.N>. ((Reuters.Briefs@thomsonreuters.com;;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4644139": {
        "id": 4644139,
        "significance": "1",
        "headline": "Abbvie Inc Expects Return To Strong Top-Line Growth In 2025",
        "description": "Jan 10 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE - EXPECT RETURN TO STRONG TOP-LINE GROWTH IN 2025, WITH HIGH-SINGLE DIGIT CAGR THROUGH REMAINDER OF DECADE.ABBVIE-EXPECT GLOBAL ONCOLOGY REVENUE TO DECLINE TO ABOUT $5.7 BILLION IN 2023,REMAIN RELATIVELY FLAT THROUGH 2024\\/2025, FOLLOWED BY RETURN TO GROWTH IN 2026.ABBVIE INC - NOW EXPECT COMBINED RISK-ADJUSTED 2025 GLOBAL SALES OF >$17.5 BILLION FOR SKYRIZI AND RINVOQ.ABBVIE INC- COMBINED PEAK SALES FOR SKYRIZI AND RINVOQ EXPECTED TO EXCEED HUMIRA PEAK REVENUE (>$21 BILLION ) IN 2027.",
        "parentTopics": "Corporate Guidance"
    },
    "4657554": {
        "id": 4657554,
        "significance": "1",
        "headline": "Abbvie Q4 Revenue Misses Estimates",
        "description": "Feb 9 (Reuters) - Abbvie Q4 EPS USD 1.38.:.",
        "parentTopics": "Corporate Guidance"
    },
    "4657698": {
        "id": 4657698,
        "significance": "1",
        "headline": "Abbvie CEO Says Expect U.S. Humira Sales To Be Down About 37% In 2023",
        "description": "Feb 9 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE CEO SAYS EXPECT U.S. HUMIRA SALES TO BE DOWN ABOUT 37% IN 2023, PREVIOUS PROJECTION WAS DECLINE OF 35% TO 55%.ABBVIE CEO SAYS EXPECT SKYRIZI AND RINVOQ TO COLLECTIVELY GENERATE $11.1 BILLION OF REVENUE IN 2023.ABBVIE CEO SAYS ANTICIPATE 2024 EPS TO NOT BE LOWER THAN $10.70 PER SHARE.ABBVIE EXEC SAYS ANTICIPATE HUMIRA SALES EROSION TO BE MORE HEAVILY WEIGHTED TOWARDS SECOND HALF OF 2023.ABBVIE EXEC SAYS IF WE SIGNIFICANTLY OVER ACHIEVE FORECAST IN 2023, THERE'S GREATER RISK OF HUMIRA SALES EROSION MOVING INTO 2024.ABBVIE EXEC SAYS PRESSURE ON CANCER DRUG IMBRUVICA LIKELY TO EASE BY 2024.Further company coverage: ABBV.N. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4688157": {
        "id": 4688157,
        "significance": "1",
        "headline": "Abbvie- Reported GAAP Earnings,Adjusted Non-GAAP Earnings For Q1 Expected To Include Acquired Ipr&D And Milestones Expense Of $150 Million On Pre-Tax Basis",
        "description": "April 5 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE- REPORTED GAAP EARNINGS,ADJUSTED NON-GAAP EARNINGS FOR Q1 EXPECTED TO INCLUDE ACQUIRED IPR&D AND MILESTONES EXPENSE OF $150 MILLION ON PRE-TAX BASIS.ABBVIE- FY 2023 ADJUSTED DILUTED EARNINGS PER SHARE GUIDANCE RANGE, INCLUDING IMPACT OF Q1 2023 ACQUIRED IPR&D AND MILESTONES EXPENSE, IS $10.62 - $11.02.ABBVIE INC-  Q1 2023 ADJUSTED DILUTED EPS GUIDANCE RANGE, INCLUDING IMPACT OF Q1 2023 ACQUIRED IPR&D AND MILESTONES EXPENSE, IS $2.31 - $2.41.Further company coverage: ABBV.N. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4697863": {
        "id": 4697863,
        "significance": "1",
        "headline": "ABBVIE REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS",
        "description": "April 27 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS.ABBVIE INC QTRLY GLOBAL HUMIRA NET REVENUES OF $3.541 BILLION DECREASED 25.2 PERCENT ON A REPORTED BASIS .ABBVIE INC RAISES 2023 ADJUSTED DILUTED EPS GUIDANCE RANGE FROM $10.62 - $11.02 TO $10.72 - $11.12.ABBVIE INC QTRLY GLOBAL SKYRIZI NET REVENUES WERE $1.360 BILLION, AN INCREASE OF 44.7 PERCENT ON A REPORTED BASIS.ABBVIE INC QTRLY GLOBAL RINVOQ NET REVENUES WERE $686 MILLION.ABBVIE INC QTRLY GLOBAL IMBRUVICA NET REVENUES WERE $878 MILLION, A DECREASE OF 25.2 PERCENT.",
        "parentTopics": "Corporate Guidance"
    },
    "4730896": {
        "id": 4730896,
        "significance": "1",
        "headline": "Abbvie Sees Adjusted Non-GAAP Earnings For Q2 To Include Acquired Ipr&D And Milestones Expense Of $280 Mln On Pre-Tax Basis",
        "description": "July 6 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE SEES REPORTED GAAP EARNINGS AND ADJUSTED NON-GAAP EARNINGS FOR Q2 TO INCLUDE ACQUIRED IPR&D AND MILESTONES EXPENSE OF $280 MILLION ON PRE-TAX BASIS.Q2 ADJUSTED DILUTED EARNINGS PER SHARE GUIDANCE RANGE, INCLUDING THE IMPACT OF Q2 2023 ACQUIRED IPR&D AND MILESTONES EXPENSE, IS $2.75 - $2.85.FY23 ADJUSTED DILUTED EARNINGS PER SHARE GUIDANCE RANGE, INCLUDING IMPACT OF Q2 2023 ACQUIRED IPR&D & MILESTONES EXPENSE, IS $10.57 - $10.97.ACQUIRED IPR&D AND MILESTONES EXPENSE TO HAVE UNFAVORABLE IMPACT OF $0.15 TO BOTH EARNINGS PER SHARE AND ADJUSTED EARNINGS PER SHARE IN Q2.Q2 EARNINGS PER SHARE VIEW $2.93 -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $2.93 -- REFINITIV IBES DATA.FY2023 EARNINGS PER SHARE VIEW $10.97 -- REFINITIV IBES DATA.",
        "parentTopics": "Corporate Guidance"
    },
    "4739851": {
        "id": 4739851,
        "significance": "1",
        "headline": "Abbvie posts Q2 EPS of USD 1.14",
        "description": "Jul 27 (Reuters) - Abbvie Q2 adjusted gross margin 84.7%.:.",
        "parentTopics": "Corporate Guidance"
    },
    "4770074": {
        "id": 4770074,
        "significance": "1",
        "headline": "Abbvie Says Reported GAAP Earnings, Adjusted Non-GAAP Earnings For Q3 Expected To Include Acquired IPR&D And Milestones Expense Of $66 Million On Pre-Tax Basis",
        "description": "Oct 4 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE - REPORTED GAAP EARNINGS, ADJUSTED NON-GAAP EARNINGS FOR Q3 EXPECTED TO INCLUDE ACQUIRED IPR&D AND MILESTONES EXPENSE OF $66 MILLION ON PRE-TAX BASIS.ABBVIE - Q3 ADJUSTED DILUTED EARNINGS PER SHARE GUIDANCE RANGE, INCLUDING IMPACT OF Q3 2023 ACQUIRED IPR&D AND MILESTONES EXPENSE, IS $2.76 - $2.86.ABBVIE - FY ADJUSTED DILUTED EARNINGS PER SHARE GUIDANCE RANGE, INCLUDING IMPACT OF Q3 2023 ACQUIRED IPR&D & MILESTONES EXPENSE, IS $10.86 - $11.06.Further company coverage: ABBV.N. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4779657": {
        "id": 4779657,
        "significance": "1",
        "headline": "Abbvie Raises 2023 Adjusted Earnings Per Share Outlook To $11.19 -$11.23",
        "description": "Oct 27 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE QTRLY EARNINGS PER SHARE $1.00.ABBVIE: RAISES 2023 ADJUSTED EARNINGS PER SHARE OUTLOOK TO $11.19 -$11.23.ABBVIE QTRLY NET REVENUE $13.93 BILLION VERSUS IBES ESTIMATE $13.71 BILLION.ABBVIE QTRLY ADJUSTED EARNINGS PER SHARE $2.95 VERSUS IBES ESTIMATE $2.86.ABBVIE: QTRLY RESULTS INCLUDE UNFAVORABLE IMPACT OF $0.04\\/SHARE FROM ACQUIRED IPR&D & MILESTONES EXPENSE.ABBVIE QTRLY GLOBAL HUMIRA NET REVENUE $3.55 BILLION, DOWN 36.2%.ABBVIE: RAISES 2024 ADJUSTED EARNINGS PER SHARE OUTLOOK FLOOR TO $11.00.ABBVIE QTRLY GLOBAL SKYRIZI NET REVENUE $2.13 BILLION, UP 52.1%.FY2024 EARNINGS PER SHARE VIEW $11.08 -- REFINITIV IBES DATA.ABBVIE QTRLY GLOBAL RINVOQ NET REVENUE $1.11 BILLION, UP 59.8%.ABBVIE: RAISES QUARTERLY DIVIDEND BY 4.7% TO $1.55\\/SHARE.FY2023 EARNINGS PER SHARE VIEW $11.05 -- REFINITIV IBES DATA.Further company coverage: <ABBV.N>. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4817423": {
        "id": 4817423,
        "significance": "1",
        "headline": "Abbvie Qtrly Adj EPS $2.79 Vs LSEG IBES Estimate $2.77",
        "description": "Feb 2 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE QTRLY ADJUSTED EARNINGS PER SHARE $2.79 VERSUS LSEG IBES ESTIMATE $2.77.ABBVIE QTRLY WORLDWIDE NET REVENUE $14.30 BILLION VERSUS LSEG IBES ESTIMATE $14.02 BILLION.ABBVIE QTRLY EARNINGS PER SHARE $0.46.FY2024 EARNINGS PER SHARE VIEW $11.24 -- LSEG IBES DATA.ABBVIE SEES 2024 ADJUSTED EARNINGS PER SHARE $11.05 TO $11.25.ABBVIE: REAFFIRMS VIEW FOR HIGH SINGLE-DIGIT COMPOUND ANNUAL REVENUE GROWTH RATE THROUGH 2029.ABBVIE: RAISES 2027 COMBINED SALES OUTLOOK FOR SKYRIZI & RINVOQ TO MORE THAN $27 BILLION.ABBVIE: RAISES PEAK SALES VIEW FOR UBRELVY & QULIPTA TO MORE THAN $3 BILLION COMBINED.ABBVIE QTRLY GLOBAL HUMIRA NET REVENUE $3.30 BILLION, DOWN 40.8%.ABBVIE: IMMUNOGEN & CEREVEL DEALS EXPECTED TO CLOSE IN MID-2024.ABBVIE QTRLY GLOBAL SKYRIZI NET REVENUE $2.39 BILLION, UP 51.9%.ABBVIE: 2024 ADJUSTED EARNINGS PER SHARE VIEW INCLUDES $0.32\\/SHARE DILUTIVE IMPACT FROM IMMUNOGEN & CEREVEL THERAPEUTICS DEALS.ABBVIE QTRLY GLOBAL RINVOQ NET REVENUE $1.26 BILLION, UP 62.9%.ABBVIE: QTRLY RESULTS INCLUDE UNFAVORABLE IMPACT OF $0.15\\/SHARE FROM ACQUIRED IPR&D & MILESTONES EXPENSE.",
        "parentTopics": "Corporate Guidance"
    },
    "4817506": {
        "id": 4817506,
        "significance": "1",
        "headline": "AbbVie expects Humira sales erosion of roughly 36% in the U.S. in 2024",
        "description": "Feb 2 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE EXEC SAYS SKYRIZI AND RINVOQ EXPECTED TO MAKE ABOUT $16 BLN IN 2024 - CONF. CALL.ABBVIE EXEC SAYS THERE WILL BE SOME STEP DOWN IN HUMIRA COVERAGE YEAR OVER YEAR, BUT DRUG WILL STILL HAVE PARITY ACCESS TO BIOSIMILARS FOR VAST MAJORITY OF US PATIENT LIVES - CONF. CALL.ABBVIE EXEC SAYS ANTICIPATE ECONOMIC HEADWINDS FOR AESTHETIC PORTFOLIO TO CONTINUE IN CHINA OVER THE NEAR TERM - CONF. CALL.ABBVIE EXEC SAYS 2024 FORECAST INCLUDES HUMIRA SALES OF $9.6 BILLION, INCLUDING US EROSION OF ROUGHLY 36% - CONF. CALL.ABBVIE EXEC SAYS EXPECT 2024 SKYRIZI REVENUE OF $10.5 BILLION AND RINVOQ SALES OF $5.5 BILLION - CONF. CALL.ABBVIE EXEC SAYS EXPECT HUMIRA GLOBAL REVENUE OF $2.2 BILLION IN Q1, INCLUDING US SALES OF $1.7 BILLION - CONF. CALL.ABBVIE EXEC SAYS STARTED TO SEE U.S. TOXIN MARKET RECOVER AT THE END OF 2023 AND EXPECT THAT TO CONTINUE IN 2024 - CONF. CALL.ABBVIE EXEC SAYS SEE SURGE IN DEMAND FOR GLP-1 WEIGHT-LOSS DRUGS AS A LONG-TERM TAILWIND FOR CO'S AESTHETICS BUSINESS - CONF. CALL.Further company coverage: ABBV.N. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4821505": {
        "id": 4821505,
        "significance": "1",
        "headline": "Abbvie Completes Acquisition Of Immunogen",
        "description": "Feb 12 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE COMPLETES ACQUISITION OF IMMUNOGEN.ABBVIE REAFFIRMS PREVIOUSLY ISSUED 2024 FULL-YEAR ADJUSTED DILUTED EPS GUIDANCE RANGE OF $11.05-$11.25.UPDATES PREVIOUSLY ISSUED 2024 FIRST-QUARTER ADJUSTED DILUTED EPS GUIDANCE RANGE FROM $2.30-$2.34 TO $2.26-$2.30.FIRST-QUARTER ADJUSTED DILUTED EPS NOW INCLUDES A $0.04 PER SHARE DILUTIVE IMPACT RELATED TO IMMUNOGEN ACQUISITION.ABBVIE- 2024 ADJUSTED EPS GUIDANCE INCLUDES $0.42 PER SHARE DILUTIVE IMPACT RELATED TO COMPLETED IMMUNOGEN ACQUISITION,PENDING CEREVEL THERAPEUTICS ACQUISITION.Q1 EARNINGS PER SHARE VIEW $2.35 -- LSEG IBES DATA.FY2024 EARNINGS PER SHARE VIEW $11.19 -- LSEG IBES DATA.",
        "parentTopics": "Corporate Guidance"
    }
}